Unleash metformin: reconsideration of the contraindication in patients with renal impairment.
about
Update on the treatment of type 2 diabetes mellitusGlycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort.Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial.Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Metformin in patients with type 2 diabetes and kidney disease: a systematic review.Prevalence of Metformin Use and the Associated Risk of Metabolic Acidosis in US Diabetic Adults With CKD: A National Cross-Sectional Study.Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?Renal PET-imaging with (11)C-metformin in a transgenic mouse model for chronic kidney disease.Pharmacist review prevents evolving metformin-associated lactic acidosis.Metformin associated lactic acidosis (MALA): clinical profiling and management.Cardiovascular Drugs and Metformin Drug Dosage According to Renal Function in Non-Institutionalized Elderly Patients.Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines
P2860
Q28073342-E34FCAD2-1BE2-4707-AB73-AEB6671CE47EQ31107244-BE0DF02C-23FF-4BD9-B528-90CE9BDF0EFCQ31132421-50F8D289-DB93-4A1C-8BBB-B0D91A5E104AQ33705903-942382EC-E3AB-45DA-BB6F-8BDDD4EA7AB8Q34457919-6AB12116-33C2-4CEA-8094-91F8A1CB00A5Q35533239-E656183B-9A39-43C0-8BE2-A66A41DEE0CCQ36420975-C19A2792-FDA9-490E-BA69-77AC1DD113F8Q36531654-8B6EA378-FE01-4488-9AF0-53E4B44DBAB0Q37034003-0D8C3192-8A03-49F8-9513-95FABC1D7CB8Q38225699-53ECF8BF-AF94-4CBE-B30F-C69727CFBE47Q38708321-6F6A253C-837A-46C3-90B1-B21BF86A2226Q40907977-6BE97D73-6616-4805-9865-59A823D225B6Q50054523-C8890439-FE30-44D4-B37D-075B3A710015
P2860
Unleash metformin: reconsideration of the contraindication in patients with renal impairment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Unleash metformin: reconsidera ...... atients with renal impairment.
@en
type
label
Unleash metformin: reconsidera ...... atients with renal impairment.
@en
prefLabel
Unleash metformin: reconsidera ...... atients with renal impairment.
@en
P2093
P2860
P356
P1476
Unleash metformin: reconsidera ...... atients with renal impairment.
@en
P2093
Jennifer Defilippi
Wenya R Lu
P2860
P304
P356
10.1177/1060028013505428
P407
P577
2013-10-10T00:00:00Z